CLN Stat
PermalinkRecommendFacebookEmailComments
Companion diagnostics (CDx) are becoming more and more essential to a drug’s regulatory approval and clinical use, writes Arron S.L. Xu, PhD, in the September issue of CLN. Pharmaceutical companies have come to rely on genomic biomarkers to elucidate disease pathways, stratify patient populations, ...(Read More)
PermalinkRecommendFacebookEmailComments
Might we one day see new ways to diagnose and manage celiac disease (CD)? An article published in September in CLN probes just that question, taking an in-depth look at where research stands on an illness for which scientists thought they had all the answers. “Evidence shows that CD, an intestinal ...(Read More)
PermalinkRecommendFacebookEmailComments
Marcia Zucker, PhD, chair of AACC’s Critical and Point of Care Testing Division, writes in the latest CLN Bench Matters article that prothrombin time (PT), a global test of coagulation, is challenging to measure in that it assesses the interaction of more than a dozen enzymes within a blood sample....(Read More)
PermalinkRecommendFacebookEmailComments
Community labs—which have been under financial stress for some time due to Congressional changes to the clinical laboratory fee schedule and tough tactics from private payers looking to contain costs—are facing a challenge to survive. The September issue of Clinical Laboratory News (CLN) explores t...(Read More)
1 - 4 Next